Prescription

Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme

Retrieved on: 
Monday, March 18, 2024
Psilocybin, Depression, Patient, Research, MDXX, Sale, BHC, Ahmad Adaya, Prescription, GMP, Clinical trial, OTC, Authorization, MDMA, Special access program, Pharmaceutical industry

Ltd. (Cortexa), in what is an Australian and the Company believes a world first, has supplied GMP Psilocybin for therapeutic use outside of a clinical trial to a patient under the authorised prescriber scheme.

Key Points: 
  • Ltd. (Cortexa), in what is an Australian and the Company believes a world first, has supplied GMP Psilocybin for therapeutic use outside of a clinical trial to a patient under the authorised prescriber scheme.
  • The patient was being treated with Psilocybin for treatment resistant depression.
  • In doing so, Cortexa is now established as the only Australian company able to immediately supply and deliver both GMP MDMA and Psilocybin for both clinical trials and prescriptions via the TGA’s Authorised Prescriber Scheme.
  • Cortexa has created a national network of relationships with research institutes, key opinion leaders and emerging clinicians, and supported psychiatrists for obtaining their authorised prescriber status.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, March 18, 2024
Apoptosis, Patient, AMX0035, Science, New York Community Bank, NYCB, P.C, Initiative, ACL, Scientific misconduct, IBD, Confidentiality, Safety, Injury, Data management, Food, Signature, Cassava Sciences, ALS, Alzheimer's disease, Defendant, Food and Drug Administration, Journal, Amyotrophy, News, Prescription, Amylyx Pharmaceuticals, Dentist, FDA, City University, Biomarker, Dermatology, Complaint, Investor's Business Daily, Neurobiology of Aging, Cognition, Assumption, Category, BBC World Service, Evercore, Cassava, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Friday, March 15, 2024
Prior, Apoptosis, ALS, District court, Patient, AMX0035, Amyotrophy, Ext, LLP, Prescription, IBD, Complaint, Pomerantz, Action Replay, Food, Court, Evercore, Person, Pharmaceutical industry

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Research, Certification, Quarter, Prevalence, Teva Pharmaceuticals, Gastrointestinal disease, Partnership, ACG, Metoclopramide, Patient, Pharmacy, Gastroparesis, Health care, Holocene, Prescription, Orange Book, Marketing, Gastroenterology, Woman, DDW, PBM, Hospital, Pharmaceutical industry

SOLANA BEACH, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and recent corporate developments.

Key Points: 
  • Our commercial team’s dedicated efforts yielded a 107% increase in year-over-year revenue,” stated Dave Gonyer, R.Ph., CEO of Evoke Pharma.
  • Research and development expenses totaled approximately $23,000 for the fourth quarter of 2023 compared with $27,000 for the fourth quarter of 2022.
  • For the fourth quarter of 2023 selling, general and administrative (SG&A) expenses were approximately $3.5 million compared with $2.3 million for the fourth quarter of 2022.
  • Total operating expenses for the fourth quarter of 2023 were approximately $3.6 million compared with $2.3 million for the same period of 2022.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Retrieved on: 
Thursday, March 14, 2024
Patient, LLP, Prescription, IBD, Investor's Business Daily, Amylyx Pharmaceuticals, Advertising, Court, BBC World Service, Evercore, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amylyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

Retrieved on: 
Wednesday, March 13, 2024
Orphan drug, Growth, NESS, Nevoid basal-cell carcinoma syndrome, Disease, Patient, Research, European Medical Association, NDA, Acquisition, Prescription, EMA, Dermatology, Clinical trial, IQVIA, BCC, FDA, Sol–gel process, Carcinoma, Food, Pharmaceutical industry

On November 30, 2023, Sol-Gel announced that it had begun Phase 3 testing of SGT-610 for Gorlin syndrome, with the first patient screened.

Key Points: 
  • On November 30, 2023, Sol-Gel announced that it had begun Phase 3 testing of SGT-610 for Gorlin syndrome, with the first patient screened.
  • In addition, TWYNEO increased its broad commercial formulary coverage, with over 6 million additional lives covered between December 2022 and December 2023 per MMIT Analytics.
  • Based on Sol-Gel's financing and adoption of cost-saving measures during 2023, the company continues to maintain its cash runway into the second half of 2025.
  • The decrease in revenues in 2023 resulted mainly from the milestone payment from Galderma related to the FDA approval of Epsolay in 2022.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, March 13, 2024
Apoptosis, Patient, AMX0035, Science, P.C, Prospectus, Initiative, Form, Public expenditure, Scientific misconduct, IBD, Graphite, Safety, Data management, EAF, Reuters, Register, Food, Cassava Sciences, ALS, Alzheimer's disease, Uber, Defendant, Journal, Amyotrophy, News, Prescription, IPO, Particulates, Amylyx Pharmaceuticals, FDA, Sustainable development, DoorDash, Health, Environment, City University, Biomarker, Electrode, Cassava, Complaint, GrafTech, Investor's Business Daily, Neurobiology of Aging, Cognition, Government, BBC World Service, Evercore, Pharmaceutical industry

The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.

Key Points: 
  • The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.
  • The Company offers its services through a mobile application and website, while also providing software-as-a-service solutions to retailers.
  • In addition, the complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

Gastrointestinal Therapeutics and Diagnostics Technologies and Global Markets Report 2024-2028: Growing Trend toward Screening and Preventive Care and Adoption and Approval of Biological Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Pharmaceutical, Health, Medical Devices, Sanofi, Growth, Prevalence, AbbVie, Environment, Laxative, Incidence, Antacid, ESG, Gastroesophageal reflux disease, Malignancy, Constipation, Diarrhea, GI, GERD, Irritable bowel syndrome, Prescription, Inflammatory Bowel Diseases, Gastrointestinal disease, OTC, Therapy, Pancreatitis, IBS, Endoscopy, USD, PPI

The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The Global Gastrointestinal Therapeutics and Diagnostics Market was valued at USD 86 Billion in 2023, and is expected to reach USD 122.5 Billion by 2028, rising at a CAGR of 7.30%.
  • This research study analyzes the GI diagnostics and therapeutics market, offers revenue forecasts, assesses future trends and provides strategic recommendations for the success of market participants.
  • This report estimates market data for 2022 (the base year) and forecasts for 2023 through 2028.

Sam's Club Membership Review (2024): Sam’s Club and Plus Memberships Deals Reviewed by Compare Before Buying

Retrieved on: 
Wednesday, April 3, 2024
Retail, Home Goods, Discount, Variety, Food, Beverage, Sam's Club, Gasoline, Prescription, Scan, Walmart, Club, Bonus, Life insurance

Compare Before Buying, a leading platform for insightful consumer reviews, has published an in-depth exploration into the world of Sam's Club membership benefits.

Key Points: 
  • Compare Before Buying, a leading platform for insightful consumer reviews, has published an in-depth exploration into the world of Sam's Club membership benefits.
  • A standard Sam's Club membership is priced at $50 annually, while a Sam's Club Plus membership costs $110 per year.
  • For a limited time, however, Sam’s Club is offering the Club membership for $25 — a 50% discount — and the Plus membership with $40 off .
  • For a more thorough review of Sam’s Club membership, please visit the Compare Before Buying website .

Is A Sam’s Club Membership Worth It? 2024 Comprehensive Review Published By Compare Before Buying

Retrieved on: 
Tuesday, April 2, 2024
Online Retail, Retail, Other Retail, Department Stores, Supermarket, Specialty, Plus, Habit, Sam, Scan, Meat, Electronics, Club, Sam's Club, Prescription, Pharmacy, Mastercard, Grocery store

Best Membership-based Warehouse Retail Store:

Key Points: 
  • Best Membership-based Warehouse Retail Store:
    Sam’s Club Membership - check out a wide selection of products at competitive prices.
  • Based on the provided sources, shopping at a membership-based warehouse store like Sam's Club offers several advantages.
  • Whether stocking up on everyday essentials or splurging on special treats, Sam's Club offers a comprehensive shopping experience that combines savings with quality products.
  • These advantages should be considered when evaluating whether a Sam's Club membership aligns with individual shopping habits and preferences.